ArticleCritical care (London, England)2026
Mental health sequelae and management in survivors of cardiogenic shock: a nationwide population-based study.
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the incidence of new-onset mental disorders after cardiogenic shock (CS) and their association with long-term clinical outcomes, and to examine whether the use of psychiatric medications following diagnosis is associated with improved prognosis.
methodsA nationwide population-based cohort study was performed using the Korean National Health Insurance Service database. All adult patients who were admitted to intensive care units (ICUs) for CS between January 2012 and December 2022 and survived hospital discharge were recruited. Patients with pre-existing psychiatric diagnoses were excluded, Finally, 112,297 patients were included in the current cohort. The primary analysis assessed the association between new-onset psychiatric disorders after hospital discharge and long-term clinical outcomes among survivors of CS, with the onset of newly developed mental disorders treated as a time-varying variable. Among patients diagnosed with a psychiatric disorder, a secondary analysis assessed the association between psychiatric medication use including antidepressants, antipsychotics, anxiolytics, or sedative-hypnotics and clinical outcomes. Medication use was also modeled as a time-varying covariate. The primary endpoint was a composite of all-cause death, myocardial infarction, stroke, coronary revascularization, or heart failure hospitalization.
resultsDuring the median follow-up of 3.5 years (interquartile range: 1.26–6.56), 11,166 CS survivors (9.9%) developed new-onset mental disorders (including depressive disorder, insomnia, anxiety disorder, and schizophrenia spectrum disorder). These disorders were associated with a significantly increased risk of primary endpoint (adjusted-HR:1.08, 95%CI:1.04–1.13), except anxiety disorders. Among patients with mental disorders, initiation of medication for mental disorders was associated with a 44% reduction in the primary endpoint (adjusted-HR:0.56, 95%CI:0.53–0.59) and a 49% reduction in all-cause death (adjusted-HR:0.51, 95%CI:0.48–0.55).
conclusionsNew-onset mental disorders are common and prognostically significant in survivors of CS. Timely pharmacologic intervention for mental disorders may substantially improve long-term clinical outcomes and should be integrated into post-ICU care pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.